Table 1 Characteristics of patients
Locally advanced n (%) | Metastatic n (%) | |
|---|---|---|
Characteristics | n =9 | n =12 |
Age (years) | ||
Median | 57 | 63 |
Range | 23–71 | 31–73 |
Sex | ||
Male | 3 (33) | 4 (33) |
Female | 6 (67) | 8 (67) |
Performance status | ||
0 | 5 (56) | 5 (42) |
1 | 4 (44) | 7 (58) |
Primary tumour localisation | ||
Gland of palate | 4 (44) | 2 (17) |
Lacrimal gland | 1 (11) | 1 (8) |
Submandibular gland | — | 2 (17) |
Maxillary sinus gland | 1 (11) | 2 (17) |
Parotid gland | — | 2 (17) |
Base of tongue | 1 (11) | — |
Nasopharynx | — | 2 (17) |
Lung | — | 1 (8) |
Tracheal gland | 2 (22) | — |
Metastasis localisation | ||
Lung | — | 3 |
Lymph node | — | 2a |
Skin | — | 1 |
Multiple | — | 6 |
Histology | ||
Cribriform | 4 (44) | — |
Solid | 1 (11) | 1 (8) |
Tubular | — | 1 (8) |
Mixed | 2 (22) | 2 (17) |
NA | 2 (22) | 8 (67) |
Grade | ||
1 | 3 (33) | 1 (8) |
2 | 2 (22) | 2 (17) |
3 | 2 (22) | 1 (8) |
NA | 2 (22) | 8 (67) |
Perineural invasion | ||
Yes | 2 (22) | 2 (17) |
No | 5 (56) | 3 (25) |
NA | 2 (22) | 7 (58) |
Tumour stage at diagnosis | ||
T1 | — | 2 (16) |
T2 | 1 (11)b | 4 (33) |
T3 | 2 (22)b | 3 (25) |
T4a | — | 1 (8) |
T4b | 6 (67)c | 2 (17) |
Nodal stage at diagnosis | ||
N0 | 9 (100) | 9 (75) |
N1 | — | 3 (25) |
Disease stage at enrollment | ||
Stage I | 1 (11) | — |
Stage II | 2 (22) | — |
Stage IVA | 6 (67) | — |
Stage IVC | — | 12 (100) |
Site of progression | ||
Lung | 1 (11) | 6 (50) |
Local | 4 (44) | — |
Skin | 1 (8) | |
Dura | 1 (8) | |
Bone | 1 (8) | |
Orbit | 1 (8) | |
EGFR status | ||
2+ | 6 (67) | 8 (67) |
3+ | 3 (33) | 4 (33) |
Best response | ||
CR | 2 (22) | — |
PR | 2 (22) | 5 (42) |
SD ⩾18 months | 2 (22) | 5 (42) |
SD <18 months | 3 (33) | 2 (17) |
PD | — | — |
